275 related articles for article (PubMed ID: 38362962)
21. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
22. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet.
Bourgeois T; Jalil A; Thomas C; Magnani C; Le Guern N; Gautier T; Pais de Barros JP; Bergas V; Choubley H; Mazzeo L; Menegaut L; Josiane Lebrun L; Van Dongen K; Xolin M; Jourdan T; Buch C; Labbé J; Saas P; Lagrost L; Masson D; Grober J
J Lipid Res; 2021; 62():100013. PubMed ID: 33518513
[TBL] [Abstract][Full Text] [Related]
23. Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet.
Wang B; Rong X; Duerr MA; Hermanson DJ; Hedde PN; Wong JS; Vallim TQ; Cravatt BF; Gratton E; Ford DA; Tontonoz P
Cell Metab; 2016 Mar; 23(3):492-504. PubMed ID: 26833026
[TBL] [Abstract][Full Text] [Related]
24. Lysophosphatidylcholine acyltransferase 3 knockdown-mediated liver lysophosphatidylcholine accumulation promotes very low density lipoprotein production by enhancing microsomal triglyceride transfer protein expression.
Li Z; Ding T; Pan X; Li Y; Li R; Sanders PE; Kuo MS; Hussain MM; Cao G; Jiang XC
J Biol Chem; 2012 Jun; 287(24):20122-31. PubMed ID: 22511767
[TBL] [Abstract][Full Text] [Related]
25. Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis.
Kakisaka K; Suzuki Y; Fujiwara Y; Suzuki A; Kanazawa J; Takikawa Y
J Gastroenterol Hepatol; 2019 Jul; 34(7):1256-1262. PubMed ID: 30160786
[TBL] [Abstract][Full Text] [Related]
26. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
27. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression.
Morita Y; Sakaguchi T; Ikegami K; Goto-Inoue N; Hayasaka T; Hang VT; Tanaka H; Harada T; Shibasaki Y; Suzuki A; Fukumoto K; Inaba K; Murakami M; Setou M; Konno H
J Hepatol; 2013 Aug; 59(2):292-9. PubMed ID: 23567080
[TBL] [Abstract][Full Text] [Related]
28. Liver X receptor agonist upregulates LPCAT3 in human aortic endothelial cells.
Bousquet D; Nader E; Connes P; Guillot N
Front Physiol; 2024; 15():1388404. PubMed ID: 38694208
[TBL] [Abstract][Full Text] [Related]
29. Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells.
Yamashita A; Sugiura T; Waku K
J Biochem; 1997 Jul; 122(1):1-16. PubMed ID: 9276665
[TBL] [Abstract][Full Text] [Related]
30. Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease.
Kim H; Park C; Kim TH
Cells; 2023 May; 12(9):. PubMed ID: 37174692
[TBL] [Abstract][Full Text] [Related]
31. The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Phospholipid Remodeling Modulates Insulin Sensitivity and Systemic Metabolism.
Tian Y; Mehta K; Jellinek MJ; Sun H; Lu W; Shi R; Ingram K; Friedline RH; Kim JK; Kemper JK; Ford DA; Zhang K; Wang B
Adv Sci (Weinh); 2023 Jun; 10(18):e2300416. PubMed ID: 37088778
[TBL] [Abstract][Full Text] [Related]
33. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
34. Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis.
Lin YN; Wang CCN; Chang HY; Chu FY; Hsu YA; Cheng WK; Ma WC; Chen CJ; Wan L; Lim YP
J Agric Food Chem; 2018 Nov; 66(44):11647-11662. PubMed ID: 30359008
[TBL] [Abstract][Full Text] [Related]
35. LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis.
Thomas C; Jalil A; Magnani C; Ishibashi M; Queré R; Bourgeois T; Bergas V; Ménégaut L; Patoli D; Le Guern N; Labbé J; Gautier T; de Barros JPP; Lagrost L; Masson D
Atherosclerosis; 2018 Aug; 275():409-418. PubMed ID: 29866392
[TBL] [Abstract][Full Text] [Related]
36. Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition.
Chin CF; Galam D; Gao L; Tan BC; Wong BH; Chua GL; Loke RY; Lim YC; Wenk MR; Lim MS; Leow WQ; Goh GB; Torta F; Silver DL
J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37463052
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
[TBL] [Abstract][Full Text] [Related]
38. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
Xi Y; Li H
Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
40. Inhibiting Phosphatidylcholine Remodeling in Adipose Tissue Increases Insulin Sensitivity.
He M; Li Z; Tung VSK; Pan M; Han X; Evgrafov O; Jiang XC
Diabetes; 2023 Nov; 72(11):1547-1559. PubMed ID: 37625119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
